Article citationsMore>>

Perilongo, G., Shafford, E., Maibach, R., Aronson, D., Brugières, L., Brock, P., Childs, M., Czauderna, P., MacKinlay, G., Otte, J.B., Pritchard, J., Rondelli, R., Scopinaro, M., Staalman, C., Plaschkes, J. and International Society of Paediatric Oncology—SIOPEL 2 (2004) Risk-Adapted Treatment for Childhood Hepatoblastoma Final Report of the Second Study of the International Society of Paediatric Oncology—SIOPEL 2. European Journal of Cancer, 40, 411-421.
https://doi.org/10.1016/j.ejca.2003.06.003

has been cited by the following article:

• TITLE: Hepatoblastoma in Developing Countries; Eight Years of Single Centre Experience

  AUTHORS: Sayed Abdelahamid, Reham Abdelaziz Khedr, Madeeha El Wakeel, Alaa Younes, Gehad Ahmed, Naglaa Elkinaai, Marwa Tantawy, Hanafy Ahmed Hafez

  KEYWORDS: Hepatoblastoma, Risk Factors, Survival

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.10, October 9, 2018

  ABSTRACT: Background and objectives: Although hepatoblastoma (HB) is a rare childhood tumor and constitutes only 0.9% of all pediatric cancers, there was an obvious improvement in risk stratification and prognosis over the last two decades. This study aimed to assess the outcome of HB patients treated in our center and to investigate the impact of different prognostic factors on the survival of these patients. Patients and methods: This was a retrospective study included newly diagnosed patients with HB presented to the Children Cancer Hospital Egypt (CCHE 57357), from July 2007 to June 2015. Patient’s data were analyzed for the clinical characteristics and survival outcome of the included patients. Results: One hundred twenty-four children were included during the study period with a median age of 14 months. The tumor was found occupying the entire liver in 25 patients (20%); while it was confined to one lobe in 80% of them, portal vein thrombosis was diagnosed in 10 patients, and there were 30 patients (24%) had metastatic disease at presentation. Only five patients (4%) underwent primary surgical excision, and all of them were grossly excised (stage I); 77/119 (64.7%) experienced delayed surgery after two to six courses (median, four courses) of C5VD and the overall resection rate was 66%. There were 42 patients (35.3%) failed to do surgical excision either because they still had evident metastatic disease with poor chemotherapy response, or because their tumor remained unresectable after six courses of chemotherapy. The 3-year event-free and overall survivals for the whole studied patients were 45.7% (95% CI, 36.9% - 56.7%), and 66.7% (95% CI, 57.1% - 77.8%) respectively. The 3-year EFS and OS were significantly better in those who underwent surgical excision (68.63% and 80.74% respectively, P-value 0.001). Also, the survival rates were significantly affected by the presence of metastatic disease at presentation, tumor stage and initial risk grouping of the studied patients. Conclusion: Surgical excision, tumor stage and COG risk grouping are the main prognostic variables affecting patients’ outcome. Efforts to achieve resectability of the tumor either by advanced surgical techniques or by developing effective preoperative treatment, especially for advanced and metastatic disease, are mandatory.